NorthWest Biotherapeutics Inc (NWBO)

[sukus]

DCVax-L was mentioned. Awesome. Thanks.

Autologous tumor lysate-based approaches may be preferable to shared antigens, as suggested by a study comparing parallel cohorts of autologous GBM tumor lysate-pulsed DCs versus GBM shared antigen-pulsed DCs98. This analysis found a correlation between decreased regulatory T cell (Treg) ratios and OS, including median survivals of 34 months versus 15 months favoring the autologous approach (DCVax-L), prompting an ongoing phase III trial (NCT00045968).